RxDoctor Payments Data

April Rock

Nurse Practitioner · Bryan, OHNPI 1497178222

Payments from drug & device makers

$6,612in general payments, 2019–2025

Across 337 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$496
  • Boehringer Ingelheim$382
  • Medline Industries LP$286
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$6,612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,612 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$73,978
Medicare patients
200
Services billed
1,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$111,189
FarxigaDapagliflozin Propanediol73$98,292
JardianceEmpagliflozin44$77,070
MounjaroTirzepatide32$58,762
EliquisApixaban50$58,726
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$48,421
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr59$30,100
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$12,930
Atorvastatin Calcium445$4,015
Albuterol Sulfate HfaAlbuterol Sulfate107$1,986
Losartan Potassium275$1,929
Metoprolol Succinate128$1,909
Rosuvastatin Calcium131$1,555
Lisinopril251$1,505
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$1,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,417$111,22288 claims
Novo NordiskOzempic$1,338$111,18964 claims
GSKTrelegy Ellipta, Anoro Ellipta$242$78,521123 claims
Boehringer IngelheimJardiance$382$77,07044 claims
Lilly USA, LLCMounjaro$496$58,76232 claims
PfizerEliquis$40$58,72650 claims
Almatica Pharma LLCSertraline Hcl$16$37848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Bryan

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →